SGLT2 inhibitors, including canagliflozin, reduce the likelihood of hospitalization for heart failure in people with type 2 diabetes and reduce the likelihood of stroke and myocardial infarction in people with type 2 diabetes diagnosed with atherosclerotic vascular disease [127]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.